1. بسم الله الرحمن الرحیم

2. Sickle Cell Anemia and lymphoma case presentation

3. Marzieh Sabzechian
Pediatric hematologist oncologist

4. خانم 39 ساله مبتلا به سیکل تالاسمی
اهل خوزستان
پدر :هموزیگوت سیکل سل
مادر:سیکل تالاسمی
یک خواهر ویک برادر هموزیگوت در اثر درگیری ریوی فوت کردند
علائم:
حمله های درد اندام وشکم
هپاتو اسپلنومگالی
کم خونی

5. تحت درمان با :
تزریق خون
هیدروکسی اوره
مایع درمانی ودرمان علامتی کریزهای درد
آهن زدا:دسفرال
ضمن مراجعه جهت تزریق خون بررسیهای منظم سونوگرافی شکم هریکسال،بررسی رسوب آهن قلب وکبدوآزمایشات 6 ماه یکبار انجام میشد

6. Hemoglobin S-Beta thalassemia
Beta thalassaemia gene reduces the amount of HbA that can be made
Sickle haemoglobin (HbS) + reduced HbA
Milder form of Sickle Cell Disorder than sickle cell anemia

7. Hydroxyurea
The first effective drug treatment for adults with severe sickle cell anemia reported in early 1995
Daily doses of the anticancer drug, hydroxyurea, reduced the frequency of painful crises, acute chest syndrome, needed fewer blood transfusions
Increases production of fetal hemoglobin in the blood
Fetal hemoglobin seems to prevent sickling of red cells
cells containing fetal hemoglobin tend to survive longer in the bloodstream

8. Hydroxyurea (HU) is a chemotherapeutic agent used in adults and children severely affected with sickle cell anaemia (SCA). Current indications are: recurrent painful crises, more than two acute chest syndromes, early chronic organ damage (respiratory, renal, hepatic, myocardial insufficiencies), association with an auto-immune disease or Hb level below 6 g/dL

9. تب 2سال قبل طی معاینات: لنفادنوپاتی های متعدد گردنی درد شکم شدید
افزایش اندازه کبد و تب

10. در بررسیهای رادیو لوژیک این موارد مشخص شد
لنف نودهای گردنی :3 عدد زنجیره خلفی راست و 2 عدد زنجیره خلقی چپ با اندازه های از 2×2 ، 1/5 × 2 ، 3 × 2 سانتی متر
درشکم:
افزایش اندازه کبد غیر یکنواخت 14 سانتی متر، طحال غیر یکنواخت و نسبتا بزرگ 12 سانتی متر ولنف نودهای متعدد دراطراف آئورت و مزانتر با اندازه 3×2 ، 1/5×2، 1 × 2 سانتی متر
عدم وجود آسیت

11. آسپیراسیون وبیوپسی مغز استخوان نرمال بود
گزارش سی تی اسکن ریه نرمال بود
آسپیراسیون وبیوپسی مغز استخوان نرمال بود

12. گزارش پاتولوژی بیوپسی غده لنفاوی گردنی :
B cell lymphoma(NHL(

13. CHOP rituximab

14. CHOP rituximab
prednisolone
cyclophosphamide
vincristine

15. 8سیکل شیمی درمانی دریافت کرد
در زمان کموتراپی کریز درد کاهش یافت
درزمان شیمی درمانی هیدروکسی اوره قطع شد وتزریق خون براساس عوارض شیمی درمانی صورت میگرفت

16. در مدت یکسال بعداز شیمی درمانی هیچ مشکلی نداردمجددا هیدروکسی اوره شروع شد وتزریق خون مرتب ادامه دارد
در طی این مدت کریزهای درد تکرار نشده وبررسیهای رادیولوژیک نیز نرمال است

17. REPORTS OF HEMATOLOGIC MALIGNANCIES
in patients with sickle cell anemia are rare-only two cases (Hodgkin's disease and acute myeloblastic leukemia) before 1960.
Since then, significant improvement has been made in supportive care of sickle cell anemia patients (such as early institution of antibiotics in suspected infections), and more hematological malignancies have been reported, including :
acute lymphoblastic leukemia, chronic granulocytic leukemia, multiple myeloma, malignant histiocytosis, non-Hodgkin's lymphoma, and cutaneous T cell lymphoma.

22. SCD is associated with
high proliferative rates of bone marrow cells,
chronic inflammation and
immune dysregulation
all of which could predispose to malignancy.

23. . Although extramedullary hematopoesis is
a recognized cause of reactive lymphadenopathy in sickle cell disease, but when the lymph nodes are persistent and associated with other manifestation like fever and weight loss other differential diagnosis needs to be entertained.
These include infections especially tuberculosis, malignancy, lymphoproliferative and immunologic disorders.

24. HU is the only drug that has been proven to modify the disease at short- or middle-term with an acceptable short- term toxicity . However, few data are available about the potential risk of carcinogenesis.

25. Risk of malignancies
The other issue related to the use of this cytostatic drug concerns the risk of malignancies. There is no evidence that hemoglobinopathies are associated with an increased risk of malignancy.
To date, several malignancies have been reported in patients with SCD receiving hydroxyurea but implication of this drug in the pathogenesis of these malignancies is not possible.

26. Advances in medical therapy, screening and patient education will likely prolong the life span of many patients with sickle cell disease.
The average life expectancy in patients with sickle cell disease has improved significantly.
It is plausible that the longer patient’s live with sickle cell disease the more likely they are to develop malignancies, including hematological malignancies

27. Although the relationship between these malignancies and sickle cell disease is not yet defined, the
possibility of a common chromosomal alteration has been suggested, however ,further cytogenetic studies are still needed

28. References

29. Steensma DP, Gibbons RJ, Higgs DR
Steensma DP, Gibbons RJ, Higgs DR. Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies. Blood 2005;105:
2. Paydas S. Sickle cell anemia and hematological neoplasias. Leuk Lymphoma 2002;43:
3. Dawkins FW, Kim KS, Squires RS, et al. Cancer incidence rate and mortality rate in sickle cell disease patients at Howard University Hospital: Am J Hematol 1997;55:
4. Schultz WH, Ware RE. Malignancy in patients with sickle cell disease. Am J Hematol 2003;74:
5. Brousseau DC, Panepinto JA, Nimmer M, Hoffmann RG. The number of people with sickle-cell disease in the United States: national and state estimates. Am J Hematol 2010;85:77-8.
6. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol 2010;85:403-8.
7.  Chen L, Zhuang M, Shah HQ, Lin JH. Chronic myelogenous leukemia in sickle cell anemia. Arch Pathol Lab Med 2005;129:423-4.

30. Thank you